Latest news for Steadfast Gr (OTC:SFGLF) Stock

Steadfast Group is the largest general insurance broker network in Australia and New Zealand, with almost 420 brokers and around 1,900 offices in Australia, New Zealand, Singapore, and London. Steadfast operates as both a broker and a consolidator via equity interests in insurance broker businesses, generating over AUD 13 billion of network broker gross written premium annually. Steadfast also co-owns and consolidates underwriting agencies and other complementary businesses.

STEADFAST GROUP LTD ORD by STEADFAST GROUP LTD

Steadfast Group Ltd

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs analyst Gabriela Borges upgraded the rating for Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) from Sell to Buy and raised the price target from $77 to $140. Cloudflare shares closed at $107.68 on Tuesday. <a href="https://www.benzinga.com/quote/NET/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James analyst Brian Gesuale upgraded Maximus, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMS#NYSE">MMS</a>) from Market Perform to Outperform and announced a $90 price target. Maximus shares closed at $74.65 on Tuesday. <a href="https://www.benzinga.com/quote/MMS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Peter Winter upgraded U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) from Neutral to Buy and increased the price target from $58 to $60. U.S. Bancorp shares closed at $47.83 on Tuesday. <a href="https://www.benzinga.com/quote/USB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group analyst Vijay Kumar upgraded the rating for Mettler-Toledo International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>) from In-Line to Outperform and raised the price target from $1375 to $1450. Mettler-Toledo Intl shares closed at $1,223.68 on Tuesday. <a href="https://www.benzinga.com/quote/MTD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Nicholas Campanella upgraded Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) from Equal-Weight to Overweight but lowered the price target from $91 to $84. Edison Intl shares closed at $79.84 on Friday. <a href="https://www.benzinga.com/quote/EIX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NET stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02080622/image-6-1024x590.png" alt="" class="wp-image-715066" style="width:585px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02080622/image-6-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02080622/image-6-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02080622/image-6-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02080622/image-6.png 1111w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42740135/how-to-earn-500-a-month-from-alphabet-stock">How To Earn $500 A Month From Alphabet Stock</a></li>
</ul>

News

Upgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

This Cloudflare Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Stephens &amp; Co. analyst Mike Scialla reiterates SM Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SM#NYSE">SM</a>) with a Overweight and maintains $57 price target.

Price Target

Reiteration

Stephens & Co. Reiterates Overweight on SM Energy, Maintains $57 Price Target

<ul>
<li>Kadima Neuropsychiatry Institute in La Jolla, CA to serve as flagship for an international network of clinics dedicated to treating depression and PTSD</li>
<li>Kadima's founder, David Feifel, MD, PhD, Professor Emeritus of Psychiatry at University of California San Diego, a pioneer in advanced interventional treatments for neuropsychiatric conditions such as depression and PTSD, to join Hope as Chief Medical Innovation Officer</li>
<li>Kadima is a leading investigative site for CNS and psychedelic research, and has served as the lead site in nearly all major clinical trials in this area
<ul>
<li>Acquisition expected to be immediately accretive to revenue and EBITDA for NRx</li>
</ul>
</li>
</ul>

Biotech

Asset Sales

General

NRXP

Hope Therapeutics And NRx Pharmaceuticals Plans Acquisition Of Kadima Neuropsychiatry Institute For Its International Network Of Interventional Psychiatry Clinics

NITO

N2OFF, Inc. Announces Its JV With Soltera Renewable Energy Ltd Obtained Approval Of A 111 MWp Solar PV Project In Meltz Germany

Stephens &amp; Co. analyst Trey Grooms reiterates Vulcan Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) with a Overweight and maintains $325 price target.

Stephens & Co. Reiterates Overweight on Vulcan Materials, Maintains $325 Price Target

CTCX

Carmell Therapeutics shares are trading higher after the company announced an agreement to acquire Elevai Skincare.

Stephens &amp; Co. analyst Jacob Johnson reiterates Azenta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZTA#NASDAQ">AZTA</a>) with a Overweight and maintains $60 price target.

AZTA

Stephens & Co. Reiterates Overweight on Azenta, Maintains $60 Price Target

The purchase consideration for the Acquisition is as follows:
<ul>
<li>Approximately $1.1 million in Carmell common stock at the closing of the Acquisition (the "Closing");</li>
<li>Approximately $57,000 in cash upon the sale of specified inventory existing as of the Closing;</li>
<li>Contingent earnout consideration consisting of:
<ul>
<li>5% of net sales from Elevai's existing products paid annually during the 5-year period following the Closing, and</li>
<li>a one-time milestone payment of $500,000 if Elevai's hair and scalp products achieve $500,000 in net revenue within 24 months following the Closing; and</li>
</ul>
</li>
<li>Carmell's assumption of contractual liabilities and trade payables of Elevai at the Closing.</li>
</ul>

UPDATE: Consideration Includes ~$1.1M In Carmell Common Stock, ~$57K In Cash Upon Sale Of Specified Inventory And Contingent Earnout

Kosmos Energy Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOS#NYSE">KOS</a>) shares are trading higher premarket on Thursday. The company disclosed the start of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42758754/kosmos-energy-announces-first-gas-at-the-greater-tortue-ahmeyim-lng-project-in-mauritania-and-sene" rel="noreferrer noopener">gas production at the Greater Tortue </a>Ahmeyim LNG project offshore Mauritania and Senegal, operated by BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>).
Gas from Phase 1 began flowing to the FPSO vessel on December 31, 2024, with liquefaction at the floating LNG vessel set to follow.
Phase 1 is expected to produce 2.3 million tonnes of LNG annually, with a vessel nameplate capacity of 2.7 mtpa.
The achievement of first gas marks a significant milestone for the partnership and the governments of Mauritania and Senegal, advancing their goal of becoming a key LNG production hub in West Africa.
The first LNG production is anticipated soon. The initial cargo is expected in the first quarter of 2025, at which point revenue recognition for the project will commence.
Chairman and Chief Executive Officer Andrew G. Inglis said, &#8220;Achieving first gas sets the stage for us to ramp up production and reach the ~90,000 boepd production target we set two years ago. With our key growth projects largely delivered and capex falling, Kosmos is well positioned going into 2025.&#8221;
&#8221;The company remains focused on disciplined capital allocation and the generation of free cash flow that enables us to pay down debt, reduce leverage to less than 1.5x, and enhance the financial resilience of the company.&#8220;
Following the end of the third quarter, the company stated that Equatorial Guinea achieved the startup of its first infill well, increasing gross production to approximately<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41705712/kosmos-energy-announces-third-quarter-2024-results" rel="noreferrer noopener"> 30,000 barrels of oil per day (bopd)</a>.
Investors can gain exposure to the stock via&nbsp;Clough Select Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBSE#NYSE">CBSE</a>) and Acquirers Deep Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEEP#NYSE">DEEP</a>).
Price Action: KOS shares are up 3.22% at $3.53 premarket at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41575181/crude-oil-faces-steepest-one-day-drop-in-over-two-years-energy-stocks-plunge-prices" target="_blank" rel="noreferrer noopener">Crude Oil Faces Steepest One-Day Drop In Over Two Years, Energy Stocks Plunge: Prices &#8216;Are Likely To Remain Under Pressure,&#8217; Analyst Says</a></li>
</ul>
Photo via Shutterstock.

Equities

Small Cap

Movers

Changebridge Capital Sustainable Equity ETF

CBSE

DEEP

Kosmos Energy Ignites First Gas At West Africa LNG Project: Details

The purchase consideration for the Acquisition is as follows:
<ul>
<li>Approximately $1.1 million in Carmell common stock at the closing of the Acquisition (the "Closing");</li>
<li>Approximately $57,000 in cash upon the sale of specified inventory existing as of the Closing;</li>
<li>Contingent earnout consideration consisting of:
<ul>
<li>5% of net sales from Elevai's existing products paid annually during the 5-year period following the Closing, and</li>
<li>a one-time milestone payment of $500,000 if Elevai's hair and scalp products achieve $500,000 in net revenue within 24 months following the Closing; and</li>
</ul>
</li>
<li>Carmell's assumption of contractual liabilities and trade payables of Elevai at the Closing.</li>
</ul>
As part of the Acquisition, Carmell expects to acquire the following assets of Elevai:
<ul>
<li>Product portfolio with trailing twelve-month revenue of approximately $2.5 million;</li>
<li>Commercial and product development team;</li>
<li>Finished and work-in-process inventory of approximately $1.0 million; and</li>
<li>Accounts receivable of approximately $0.03 million.</li>
</ul>

Carmell Announces Agreement To Acquire Elevai Skincare

Stephens &amp; Co. analyst Scott Fidel reiterates Alignment Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) with a Overweight and maintains $17 price target.

ALHC

Stephens & Co. Reiterates Overweight on Alignment Healthcare, Maintains $17 Price Target

Ladenburg Thalmann analyst Paul Fremont upgrades Evergy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVRG#NASDAQ">EVRG</a>) from Neutral to Buy and announces $68.5 price target.

EVRG

Ladenburg Thalmann Upgrades Evergy to Buy, Announces $68.5 Price Target

<a href="https://www.globenewswire.com/Tracker?data=N9ey61H0RSzy3MHPqX4Ek_mH9spwNW4y_xCHTqNsXxv2Eskb8dlPB_NGZ7Bg83mVTb2ZIyEugxGIYYFirYKgWA==">Cerence Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>) ("Cerence AI"), a global industry leader in AI for transportation, today announced a multi-year agreement with JLR to develop the luxury automotive's next-generation in-car experience.
The companies will partner to leverage Cerence's AI-enabled technologies to deliver advanced intelligence and capabilities to JLR customers globally. The companies will continue to work together to expand and improve the JLR in-car experience over time.

CRNC

Cerence AI Announces Multi-Year Agreement With JLR

Across the recent three months, 7 analysts have shared their insights on Castle Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $40.29, with a high estimate of $44.00 and a low estimate of $36.00. This upward trend is evident, with the current average reflecting a 14.17% increase from the previous average price target of $35.29.
<img src="https://www.benzinga.com/files/images/story/2025/1735822954_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Castle Biosciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$44.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Thomas Flaten</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Paul Knight</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$36.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$39.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$42.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Castle Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Castle Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Castle Biosciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Castle Biosciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CSTL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Castle Biosciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Castle Biosciences's Background</h2>
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
<h3>Financial Milestones: Castle Biosciences's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Castle Biosciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 39.5% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Castle Biosciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.65%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.52%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.45%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.06, Castle Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CSTL

Beyond The Numbers: 7 Analysts Discuss Castle Biosciences Stock

Ratings for Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) were provided by 17 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Carvana, revealing an average target of $250.71, a high estimate of $330.00, and a low estimate of $175.00. Observing a 24.62% increase, the current average has risen from the previous average price target of $201.18. 
<img src="https://www.benzinga.com/files/images/story/2025/1735822914_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Carvana among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Lick</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$330.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$245.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$320.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$225.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$240.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$190.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$182.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>John Colantuoni</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$185.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Michael McGovern</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$210.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Carvana. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Carvana compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Carvana's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Carvana's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CVNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Carvana analyst ratings.</a>
<h2>All You Need to Know About Carvana</h2>
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.
<h3>Carvana's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Carvana's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 31.81%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Carvana's net margin is impressive, surpassing industry averages. With a net margin of 2.33%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Carvana's ROE stands out, surpassing industry averages. With an impressive ROE of 14.95%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Carvana's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.17% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Carvana's debt-to-equity ratio surpasses industry norms, standing at 10.06. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVNA

Beyond The Numbers: 17 Analysts Discuss Carvana Stock

Stephens &amp; Co. analyst Jeff Garro reiterates Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) with a Overweight and maintains $26 price target.

PRVA

Stephens & Co. Reiterates Overweight on Privia Health Gr, Maintains $26 Price Target

WIIM

MODG

Topgolf Callaway Brands shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $11 to $13.

Ratings for Hillman Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $13.6, a high estimate of $16.00, and a low estimate of $12.00. This current average has increased by 13.33% from the previous average price target of $12.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1735822886_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Hillman Solns by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reuben Garner</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>David Manthey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$14.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Brian McNamara</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Brian McNamara</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Hillman Solns. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hillman Solns compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Hillman Solns's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Hillman Solns's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HLMN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hillman Solns analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Hillman Solns</h2>
Hillman Solutions Corp is a provider of hardware-related products and related merchandising services to retail markets in North America. The company sells its products to hardware stores, home centers, mass merchants, pet supply stores, and other retail outlets. Its product lines include thousands of small parts such as fasteners and related hardware items; threaded rod and metal shapes; keys and accessories; builder's hardware; personal protective equipment, such as gloves and eye-wear; and identification items, such as tags and letters, numbers, and signs. The segments of the group are Hardware and Protective Solutions, which is the key revenue-generating segment; Robotics and Digital Solutions; and Canada. It has a business presence in the US, Canada and Mexico.
<h3>Hillman Solns: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Hillman Solns faced challenges, resulting in a decline of approximately -1.42% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Hillman Solns's net margin excels beyond industry benchmarks, reaching 1.89%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Hillman Solns's ROE stands out, surpassing industry averages. With an impressive ROE of 0.63%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.31%, the company showcases effective utilization of assets.
Debt Management: Hillman Solns's debt-to-equity ratio stands notably higher than the industry average, reaching 0.71. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HLMN

What 5 Analyst Ratings Have To Say About Hillman Solns

HUTCHMED shares are trading higher after the company announced the divestment of its 45% interest in Shanghai Hutchison Pharmaceuticals.

Ratings for Truist Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $52.38, with a high estimate of $60.00 and a low estimate of $46.00. This upward trend is apparent, with the current average reflecting a 9.13% increase from the previous average price target of $48.00.
<img src="https://www.benzinga.com/files/images/story/2025/1735822856_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Truist Finl's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Terry McEvoy</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>David Rochester</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Scott Siefers</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$51.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Ryan Nash</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$51.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Erika Najarian</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$49.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$46.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Truist Finl. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Truist Finl compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Truist Finl's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Truist Finl's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TFC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Truist Finl analyst ratings.</a>
<h2>Discovering Truist Finl: A Closer Look</h2>
Based in Charlotte, North Carolina, Truist is the combination of BB&amp;T and SunTrust. Truist is a regional bank with a presence primarily in the Southeastern United States. In addition to commercial banking, retail banking, and investment banking operations, the company operates several nonbank segments.
<h3>Truist Finl's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Truist Finl's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 4.44%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Truist Finl's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 26.27%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Truist Finl's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.3%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Truist Finl's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.26%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Truist Finl's debt-to-equity ratio stands notably higher than the industry average, reaching 0.87. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Truist Finl Through The Eyes Of 8 Analysts

Steadfast Group Limited (AU:SDF) has released an update. Steadfast Group Limited has seen significant changes in voting power and relevant interest...

Steadfast Group Sees Shifts in Voting Power

Morgan Stanley upgraded Steadfast Group (SFGLF) to Overweight from Equal Weight with a price target of A$6.98, up from A$6.64. While the firm ackno...

Steadfast Group upgraded to Overweight from Equal Weight at Morgan Stanley

Steadfast Group Limited (AU:SDF) has released an update. Steadfast Group Limited has provided an update on its ongoing internal review of its speci...

Steadfast Group Updates on Strata Insurance Review

TimesSquare Global Small Cap Strategy Q3 2024 Commentary

Goldman Sachs analyst Julian Braganza maintained a Hold rating on Steadfast Group Limited (1S6 – Research Report) on December 4 and set a price tar...

Steadfast Group Limited (1S6) Gets a Hold from Goldman Sachs

Steadfast Group Limited (AU:SDF) has released an update. Steadfast Group Limited is set to release its first-half financial results for 2025 on Feb...

Steadfast Group to Announce H1 2025 Results

Steadfast Group Limited (AU:SDF) has released an update. Steadfast Group Limited has announced significant updates that are likely to impact its st...

Steadfast Group Limited Announces Key Financial Updates

Steadfast Group Limited (AU:SDF) has released an update. Steadfast Group Limited has announced the issuance of 5,720 unquoted equity securities und...

Steadfast Group Limited Issues New Employee Equity

Steadfast Group Limited (AU:SDF) has released an update. Steadfast Group Limited has announced the issuance of 21,294 unquoted securities as part o...

Steadfast Group's New Securities Boost Employee Incentives

Steadfast Group Limited (AU:SDF) has released an update. Steadfast Group Limited has announced the issuance of 35,335 unquoted securities as part o...

Comments

Steadfast Gr

News

Latest news for Steadfast Gr (OTC:SFGLF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga